Register & Pay Before Friday, 29th November 2019 & Save £500

10th ANNUAL WORLD adc LONDON 2020

2nd-5th March

NEW **4 STREAMS**

NEW **CMC DAY**

MORE **9 WORKSHOPS**

MORE **62+ SPEAKERS**

Europe's Longest Standing & Most Comprehensive Antibody-Drug Conjugate Conference

Trevor Hallam
Chief Scientific Officer
Sutro Bio

Thorsten Sperber
Global Head Medical Affairs
Immunomedics

Guy De Roo
Project Leader Downstream Processing
Synthon

Thomas Pillow
Senior Scientist
Genentech

Hillary Schuessler
Scientific Leader
GSK

Bart de Goeij
Assistant Director
Genmab

Jeremy Parker
Senior Principal Scientist - New Modalities & Tissue Targeting
AstraZeneca

Rakesh Dixit
Chief Executive Officer & Founder
Bionavigen

Senior Partner:

MERCK

10 YEARS

Maximise the Clinical Therapeutic Window of Your ADC at the **10th World ADC London**

Celebrating its 10th year, World ADC is returning to London bigger and better than ever. Covering the A to Z of ADCs, **World ADC London** will continue to curate and distil the field's latest scientific advances and lessons learned, particularly from the last 12 months. Join the likes of **AstraZeneca, Sanofi** and **Bayer** at this definitive forum to **maximise the therapeutic index of your ADC pipeline**.

In 2020 you will gain an unrivalled learning experience, across 4 packed days with 4 parallel tracks, including **a new track on protein engineering** and more on **clinical, regulatory and manufacturing challenges**.

As Europe's largest gathering of ADC stakeholders, seize the opportunity to **network with 320 drug developers from 160 active ADC organisations**. You'll be able to build new connections, further cement partnerships and catch up with peers.

For ADC drugs developers **World ADC London** is the most important learning and networking experience in their calendar year. Join us at the forefront of ADC science to develop the next generation of clinically impactful ADCs.

5 Reasons to Attend World ADC London

Evaluate new era innovative payloads with differentiated mechanisms of action and alternative **formats for warhead optimisation**



Learn about outsourcing the safe development and manufacture of ADCs **with perspectives from the CMOs and drug innovators**



Discover and delve into the world of alternative format conjugates **to enhance tumour penetration**



Share potential mechanisms of ADC off-target toxicities and strategies as well as opportunities to **improve the overall therapeutics index of ADCs**

Learn lessons during the drug product development of ADCs whilst **tackling stability and formulation challenges**

Contents

Agenda-at-a-Glance

Pre-conference Workshop Day
Monday, 2nd March

Introduction to ADCs	Workshop A	Workshop C	Workshop E

Lunch & Networking

Introduction to ADCs *continued*	Workshop B	Workshop D	Workshop F

Scientific Programme Day 1
Tuesday, 3rd March

Plenary Stream

Discovery Chemistry Stream	Discovery Biology Stream	Translational Steam	CMC Stream
	NEW		

Lunch & Networking

Discovery Chemistry Stream	Discovery Biology Stream	Translational Steam	CMC Stream
	NEW		

Plenary Stream

Scientific Poster Session

Scientific Programme Day 2
Wednesday, 4th March

Plenary Stream

Discovery Chemistry Stream	Discovery Biology Stream	Translational Steam	CMC Stream
	NEW		

Lunch & Networking

Discovery Chemistry Stream	Discovery Biology Stream	Translational Steam	CMC Stream
	NEW		

Plenary Stream

Post-conference Workshop Day
Thursday, 5th March

New CMC Day	Workshop G
NEW	

Lunch & Networking

New CMC Day *continued*	Workshop H
NEW	

Your 62 Expert Speakers

Alain Beck
Senior Director, Biologics CMC & Developability
Pierre Fabre

Alexie Karpov
Senior Investigator I
Novartis

Ashutosh Pathak
Vice President & Global Head, Medical Affairs
Ascentage Pharma

Andrea Gonzalez-Munoz
Research Scientist
AstraZeneca

Andrew Livingston
Professor of Chemical Engineering
Imperial College Londo

Balakumar Vijayakrishnan
Group Leader - Conjugation
AstraZeneca /Spirogen

Barbara Akla
Senior Scientist
Pierre Fabre

Bart de Goeij
Assistant Director
Genmab

Brian O'Mara
Associate Director - Downstream Process Development
Ambrx

Charles Skarbek
Bioorganic Chemistry Post-doctoral Researcher
University of Paris-Sud

Christopher A. Alabi
Associate Professor
Cornell University

Daejin Abidoye
Vice Present, Clinical Development
Seattle Genetics

Dan Custar
Associate Director - Drug Substance CMC
Mersana

Daniel Shweizer
Fellow & Project Leader
Novartis

David Bramhill
Consultant
Bramhill Consulting

Deya gonzalez
Associate Professor
University of Swansea

Ed Ha
Founding Principal Scientist
AngieX

Eric Lacoste
Head of Bio-Organic Team & Chemistry, Manufacturing, Control & Project Manager
Sanofi

Gavin Bennett
Director & Project Leader
Bicycle Therapeutics

Giorgio Salciarini
Technical Business Development Manager
BSP Pharmaceuticals

Gordon Rigg
Independent Consulant

Your 62 Expert Speakers

Guy De Roo
Project Leader, Downstream Processing
Synthon

Hans Georg Lerchen
Chief Scientist, Medicinal Chemistry
Bayer

Hillary Schuessler
Scientific Leader
GSK

Iontcho Vlahov
Vice President, Discovery Chemistry
Endocyte

Jack Wang
Senior Scientist
Johnson & Johnson

Jacopo Millul
Research Associate Scientist
Philogen

Jagath Reddy Junutula
Senior Vice President - Research & Development
Modmab Therapeutics

Jamie Baker
Reader in Chemical Biology
University College London

Jens Lorhmann
Disease Area Head - Oncology
Novartis

Jeremy Parker
Senior Principal Scientist - New Modalities & Tissue Targeting
AstraZeneca

James Jim Christie
Scientist
AstraZeneca

John Babcook
Senior Vice President of Discovery Research
Zymeworks



John Harlan
Senior Principal Research Scientist
AbbVie

Julian Andreev
Senior Staff Scientist & Research Fellow
Regeneron

Julie Desrivot-Quénelle
Project Lead - Pharmacokinetic Pharmacodynamic
Pierre Fabre

Justin Mason Home
Director
HPAPI Project Services Limited

Justin Sweeley
Senior Technology Manager, Biologics
Novasep

Keiji Furuuchi
Director, Preclinical Development Epochal Precision Anti-Cancer Therapeutics (EPAT), OBG
Eisai

Letrishka Anthony
Senior Analyst
Beacon Targeted Therpaies

Lisa McDermott
Head of Process & Analytical Development
Merck

Luc Desnoyers
Senior Director of Translational Sciences
CytomX

Your 62 Expert Speakers

Mark Frigerio
Director & Vice President - Design, Developability & Chemistry
Abzena

Markus Eser
Laboratory Head
Bayer

Martin Axon
Principal Occupational Hygienist
Safebridge Consultants

Naresh Jain
President & Chief Executive Officer
NJ Biopharmaceuticals LLC

Phil Howard
Chief Scientific Officer
Spirogen



Pierre Guibal
Deputy Head, Analytical Development, BioAnalytics
Sanofi

Prathap Kumar Mahalingaiah
Senior Scientist III
AbbVie

Rakesh Dixit
Chief Executive Officer & Founder
BioNavigen

Rich Reynolds
Principal Scientist, Conjugation Process Development
Seattle Genetics

Rick Powers
Independent Consulant

Robert Sussman
Managing Director
Safebridge Consultants

Samuele Cazzamalli
Research Scientist
Philogen

Simon Chivers
Independent Consulant

Sibylle Heidelberger
Senior Specialist - Support
Sciex

Steffan Woell
Principal Scientist
Merck

Steve Conlan
Professor
University of Swansea

Subhash Chauhan
Professor
University of Tennessee

Thomas Pillow
Senior Scientist
Genentech

Thorsten Sperber
Global Head Medical Affairs
Immunomedics

Trevor Hallam
Chief Scientific Officer
Sutro Bio

Ulf Grawunder
Chief Executive Officer & Founder
NBE Therapeutics

What's New for 2020?

4th Stream

This year we are introducing an additional discovery stream, enabling you to delve deeper into biology and chemistry separately.

Discovery Chemistry Stream

This stream will allow for a more dedicated discussion on **payload and linkers, in particular novel payloads** and how to validate what is already out there.

Discovery Biology Stream

This stream will allow for a greater focus on **novel format ADCs, antibody engineering and novel targets**. It will also enable you to delve into complex ADCs, looking at alternative formats for the antibody such as peptides and bispecifics.

The 1st CMC Day

Focussed **from Phase II through to commercial scale manufacturing**, the inaugural CMC Seminar Day will enable you to **effectively scale up your manufacturing operation**. With presentations delving into formulation and fill finish challenges, gain insights to overcome manufacturing roadblocks and analytical lessons learned.

Look out for the clinical content...

For many years now, the clinical failures have influenced how we approach drug development and furthermore scientists are sceptical of the technologies' ability until it's been clinically validated.

Clinical content has been built into the agenda at World ADC London and **any presentations that feature results or data will be highlighted with a purple box.**

Scientific Poster Session

Every year we're told the poster session is one of the highlights of World ADC London. We have evolved this session and built out the Scientific Poster Session to run for longer. Anyone can present a poster here!

Your 2020 Highlights

More Speakers, Means More Content For You

Companies Presenting at World ADC London with Phase III ADCs in the Clinic

IMMUNOMEDICS, INC.

Thorsten Sperber, Global Head Medical Affairs at Immunnomedics, will be giving a brief introduction on the unique background of SG as well as **clinical updates on metastatic TNBC and clinical update on HR+ metastatic Breast Cancer**

Prathap Kumar Mahalingaiah, Senior Scientist III at AbbVie will be reviewing mechanisms of action for antibody drug conjugate off target toxicities and **delving into opportunities to improve clinical index of ADCs**

abbvie

SeattleGenetics

Daejin Abidoye, Vice President, Clinical Development at Seattle Genetics will be sharing preclinical data demonstrating monomethyl auristatin E (MMAE) has the potential to drive immunogenic cell death. He will also be presenting data from **combinations of ADCs with PD-1 inhibitors with implications for future development of these combinations**

Innovative Content You Don't Want to Miss

SUTRO BIOPHARMA

Trevor Hallam, Chief Scientific Officer at Sutro Bio will be presenting on: **Targeted Immunostimulants; A Promising Approach to *in situ* Immunisation**

Andrea Gonzalez-Munoz, Research Scientist will be sharing AstraZeneca's work outside of oncology: **A Single Dose of Antibody-Drug Conjugate Cures a Stage 1 Model of African Trypanosomiasis**

AstraZeneca

Philogen
Innovating targeting

Samuele Cazzamali, Research Scientist at Philogen, will share an update of Philogen's: **Small Molecule-Drug Conjugates: Getting Small to Enhance Targeting**

Exciting Companies Sharing their Story:

gsk

Hillary Schuessler, Scientific Leader at GSK will be sharing the **impact of drug load and DAR of an ADC on binding and potency**

Guy de Roo, Project Leader, Downstream Processing at Synthon, will be addressing challenges and strategies for ADC manufacturing, **including process development and manufacturing of cysteine linked antibody-drug conjugates – control of product heterogeneity**

Synthon

NOVARTIS

Daniel Shweizer, Fellow and Project Leader, Novartis is sharing the lessons learned during drug product development of ADCs, **exploring new processes and establishing external partnerships**

Pre-conference Workshop Day

Monday, 2nd March

Introduction to Discovery & Design of Novel ADCs (FULL DAY) 9.00-16.00

This workshop will offer a one day intense learning environment to establish core skills and understanding in the critical areas of ADC research and development. **Designed for new entrants to the ADC field** it will deliver critical knowledge in a number of the key problem areas that hinder antibody drug conjugate programmes.

Covering essential elements in ADC discovery and early development, this workshop will enable you to:

- Gain an overview of the development process for ADCs
- Improve payload and linker design chemistry
- Understand the impact of conjugation site selection on your ADC
- Choose/choice of optimum "antibody" format
- Select the most appropriate ADC target which is easily accessible
- Learn about cellular assays
- Review the advantages and disadvantages of different preclinical animal models
- Develop early stage assays and learn how to effectively interpret the data

David Bramhill, Consultant, **Bramhill Consulting**

Workshop A: Advanced ADC Target Discovery

9.00-12.00

This workshop will offer a half-day session detailing the different aspects of ADC target development.

Aimed at those with an interest in targets, targeting it will consider key areas of this intrinsically critical.

Covering essential elements in ADC target discovery and early development, **this workshop will delve into four distinct yet interrelated themes:**

- Understanding the current pipeline of ADCs, their position in the clinical development pathway, and their selection as clinically relevant targets
- Novel ADC modalities to enhance target specificity (bispecifics/aptemers/nanobodies/peptides)
- Informatics and design, and influences on IP
- Antibody selection and production, and evaluation in trending preclinical patient derived *ex vivo* and *in vitro* models

Steve Conlan, Professor, **University of Swansea**

Workshop C: Integrated Development of ADCs - from Gene to First in Man

9.00-12.00

- Introduction: Integrated Development of ADCs
- Exploring a streamlined approach to Technical Development - tools and methods
- CMC Control and Characterisation Strategy
- Target de-risking and candidate selection strategies
- Evaluation of on-target vs off-target toxicity
- DRF studies and determining MTD
- IND-enabling non-clinical studies
- Programme Acceleration
- Topics for Health Authority Meetings
- The IND

Simon Chivers, Independent Consultant

Gordon Rigg, Independent Consultant

Workshop E: Outsourcing the Safe Development & Manufacture of ADCs: Perspectives from the CMOs & Drug Innovators

9.00-12.00

This workshop will discuss how to evaluate the **hazards and risks associated with the development and manufacture of ADCs**.

Key topics to be covered include:

- Safe handling procedures and appropriate containment and control devices necessary to prevent worker exposure and workplace contamination
- How the risks change as the development process evolves
- Requirements of CMOs and CDMOs drug innovators should look for when selecting facilities capable of safe handling of these hazardous substances

Robert Sussman, Managing Director, **SafeBridge Consultants**

Martin Axon, Principal Occupational Hygienist, **Safebridge Consultants**

Pre-conference Workshop Day

Monday, 2nd March

Workshop B: The Chemistry of Toxins, Conjugations & Linkers for Antibody-drug Conjugates

13.00-16.00

The choice of linker and payload for an ADC is essential for the selection of a successful clinical candidate. This workshop will **deepen your understanding of the chemistry behind conjugation technologies** and be led by highly experienced leaders in the ADC field who have designed successful candidates from discovery all the way to clinical trials.

Attend this workshop to:

- Understand synthetic challenges, structural features, and stability of toxins
- Analyse the chemistry of linkers, linker choice, linker release mechanisms
- Discuss site-specific conjugations vs non-site-specific conjugations
- Asses the stability of ADCs
- Evaluate mitigation of aggregation

Naresh Jain, President & Chief Executive Officer, **NJ Biopharmaceuticals LLC**

Jagath Reddy Junutula, Senior Vice President - Research & Development, **ModMab Therapeutics**

Workshop D: Lessons Learned from the Successful & Failed ADCs

13.00-16.00

The past three decades of the ADC development have provided us five approved ADCs and there is new momentum in the ADC cancer therapeutics development. But unfortunately, the vast majority of ADCs have been terminated during and prior to clinical development.

This workshop will be providing a **comprehensive review of the ADC landscape, including early and late-stage ADCs** and trends in next-generation ADC development. Major learnings from successful as well as failed targets, linkers, site-specific conjugation, cytotoxic warheads, and translational strategies will be discussed.

Gain in-depth insights into:

- Navigation of the ADC World
- Learning from targets for solid and heme tumours
- Linkers and conjugation matter
- Learnings from antibody selection for ADCs
- Translational medicine lessons

Rakesh Dixit, Chief Executive Officer & Founder, **BioNavigen**

Workshop F: Occupational Health & Safety in Delivering ADC Projects

13.00-16.00

Establishing and maintaining safe working environments when handling ADC components is imperative. Some ADC payloads are some of the most occupationally potent and toxic materials ever handled in the biopharmaceutical sector.

This workshop will **explore the practical H&S elements involved in pragmatic roll-out of ADC projects**.

Learn about scientific and systematic, business-focused integration and delivery of H&S in ADC projects, including:

- Strategic business matters, project planning, project elements and costs
- Conceptual and detailed design steps
- Deciding on control and containment
- Dealing with A&E firms and containment equipment vendors
- HPAPI H&S management systems

Justin Mason-Home, Director, **HPAPI Project Services Limited**

"Excellent talks by all the speakers with a transparent and frank attitude to share good and bad experiences gained in the challenging world of ADCs in oncology"

Menarini Group

Scientific Programme Day 1

Tuesday, 3rd March

Alain Beck
Senior Director, Biologics CMC & Developability
Pierre Fabre

8.30 **Chair's Opening Remarks**

Alain Beck
Senior Director, Biologics CMC & Developability
Pierre Fabre

8.40 **Is There Method in the Madness? What Have we Learnt from the Last Decade of ADCs**

- Review the lessons from successes and failures
- Assess 1st, 2nd, 3rd and next-generation ADCs
- Discuss ADCs to watch in 2020/2021

Hillary Schuessler
Scientific Leader
GSK

9.10 **Impact of Drug Load & DAR of an ADC on Binding & Potency**

- Identification of sites of conjugation on a cysteine-based ADC
- Impact of drug load and DAR on binding and in vitro and in vivo potency
- Understanding of the structure-function relationship of drug load and DAR

Thorsten Sperber
Global Head Medical Affairs
Immunomedics

9.40 **Sacituzumab Govitecan – A Clinical Development Update Across Multiple Indications**

Clinical Content

- A brief introduction on the unique background of SG
- Clinical update on metastatic TNBC
- Clinical update on HR+ metastatic Breast Cancer
- Clinical update on metastatic Urothelial Cancer

10.10 **Speed Networking**

This session is a great opportunity to introduce yourself to the attendees that you would like to have more in depth conversations with. This session is the ideal opportunity to get face-to-face time with many of the brightest minds working in the ADC field and establish meaningful business relationships.

11.00 **Morning Refreshments**

Scientific Programme Day 1

Tuesday, 3rd March

Discovery Chemistry Stream

Let's Focus on the New, Novel Format Payloads & Looking Outside the Payload Box

12.00 NAMPT & Eg5 Inhibitors – Two Novel Payload Classes for Antibody-drug Conjugates

- Exploring insights into discovery of two novel payload classes
- Evaluating Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors as a novel payload class with non-antimitotic mode of action
- Assessing the discovery of potent and selective ADCs with Eg5 inhibitors through linker and payload optimisation

Alexei Karpov, Senior Investigator I, **Novartis**

12.30 Novel Immune-Stimmulatory ADCs (iADCs) for Effective Targeting of Solid Tumours

- Exploring site-specific conjugates with ultra-potent anthracycline toxins
- Discovering immune-oncology function of NBE's iADCs
- Reviewing preclinical validation of a ROR1 targeting iADC

Ulf Grawunder, Chief Executive Officer & Founder, **NBE Therapeutics**

Discovery Biology Stream

Developing More Targeted & Stable ADCs with Next Generation Engineered Antibodies

12.00 Efficacy of the Antibody-Drug Conjugate W0101 in Preclinical Models of IGF-1 Receptor Overexpressing Solid Tumours

- Evaluating W0101; a unique IGF-1Rtargeted ADC, designed to deliver a highly potent cytotoxic auristatin derivative selectively to IGF-1R overexpressing tumour cells
- The monoclonal antibody (hz208F2-4) used to prepare the ADC was selected for its specific binding properties to IGF-1R compared to the insulin receptor (IR), and for its internalization properties
- Examining how W0101 induced receptor-dependent cell cytotoxicity *in vitro* when applied to various cell lines overexpressing IGF-1R but it did not affect normal cells

Barbara Akla, Senior Scientist, **Pierre Fabre**

12.30 Panel Discussion: Putting Antibodies Through the PK Case Study

- Selecting the case study that protects the antibody by increasing half life
- Modifying antibodies by increasing the half life

Translational Steam

Focusing on the Relationship of Half Life & Clearance Rates with Efficacy & Safety, to Gain Better Modelling & Improved Prediction

12.00 Phase 1 Interim Data of MORAb-202 as Eribulin Conjugated Anti FRATargeted ADC

- MORAb-202 is the first ADC which is loaded with HALAVEN® as payload
- HALAVEN® is an approved drug which exhibits unique effects on tumor microenvironment
- The interim data of MORAb-202 Phase 1 study in Japan is to be discussed

Keiji Furuuchi, Director, Preclinical Development Epochal Precision Anti-Cancer Therapeutics (EPAT), OBG, **Eisai**

Clinical Content

12.30 Full Characterisation of ADC, From Native to Peptide Mapping

- Fast characterisation of ADCs trough Native analysis
- Full characterisation of the mAb and payload
- Easy and fast DAR calculation using Biopharma view

Sibylle Heidelberger, Senior Specialist - Support, **Sciex**

CMC Stream

Securing Your Robust ADC Supply Chain & Conjugation Techniques

12.00 When to Apply Design of Experiments (DoE) to ADC Development

- Example of a DoE applied to Analytical method development
- When DoE is not an applicable tool and what can be implemented in its place
- Highlights from a project where a 2-block response surface DoE increased process robustness

Justin Sweeley, Senior Technology Manager, Biologics, **Novasep**

12.30 Nanostar Sieving Produces Precise, Unimolecular PEGs for PEGylation

- Iterative synthesis with liquid phase separations produces unimolecular (completely monodisperse) PEGs 5kDa – 20kDa
- Attachment to nanostar hub allows complete control over end-group functionalisation
- Reactive side chains can be used to deploy controlled derivitisation
- PEGYlation results in conjugates with order of magnitude less dispersity

Andrew Livingston, Professor of Chemical Engineering, **Imperial College London**

Scientific Programme Day 1

Tuesday, 3rd March

13.00 Panel Discussion: The Power of Nuclear; Reviewing Peptide Based Radioconjugate Therapy

- Delving into the exciting world of radioconjugates this panel will focus on the challenges that come with these novel formats
- Validating Tb labelled radioconjugates for cancer therapy with Auger Electrons

13.00 Targeting the Receptor for Advanced Glycation Endproducts (RAGE): An ADC Perspective

- Reviewing the preclinical development of RAGE-ADC versions
- Focusing on ovarian cancer
- Update on Swansea ADC clinical pipeline and development platforms

Deya Gonzalez, Associate Professor, **University of Swansea**

Clinical Content

13.00 Translational Modelling for a Novel ADC to Support Safe & Efficacious Dosing Regimen in Patients

- A PKPD model was developed using PK and tumour growth data collected from mouse xenograft tumour and allow to characterize the tumour-static concentrations (TSC) where the tumour growth and killing rates nullify each other
- Targeting trough concentrations of W0101 above the *in vivo* TSC value, a clinical efficacious dosing regimen could be predicted
- A PK-Toxicodynamic model was developed to characterize ADC induced toxicity in monkey and used to simulate potential patient outcomes

Julie Desrivot-Quénelle, Project Lead - Pharmacokinetic Pharmacodynamic, **Pierre Fabre**

13.00 Thinking to the Future of ADCs

- Reviewing the complexity of supply chain for ADCs
- Securing commercial supply
- Looking to the future of ADCs

Giorgio Salciarini, Technical Business Development Manager, **BSP Pharmaceuticals**

13.30 Lunch & Networking

Refreshing the "Middle-Man", Looking at & Enhancing Novel Linker Technologies

15.00 OligoTEA Linkers: A Platform for Multifunctional Antibody Conjugates & Quantification of Intracellular Processes

- Reviewing site-specific conjugation techniques
- Understanding how sequence-defined linkers affect *in vitro* ADC potency
- Analysing the quantification of intracellular bond degradation rate

Christopher A. Alabi, Associate Professor, **Cornell University**

Delving into the World of Alternative Format Conjugates to Enhance Tumour Penetration

15.00 Encoded Self-Assembling Chemical Libraries for the Discovery of New Small Molecules for Tumour-Associated Antigens

- High-Throughput Screening represented for years the main screening technology for the selection of novel small ligands to target Tumor-Associated Antigens. Nevertheless, most efficient and fastest screening methods are required
- ESAC (Encoded Self-Assembling Chemical Libraries) technology is a valid alternative to classic screening method to identify different small ligands against Tumour-Associated Antigens that can be used for drug delivery and imaging of solid tumours and metastatic lesions

Jacopo Millul, Research Associate Scientist, **Philogen**

Building your ADC Toolkit; Exploring the Best *in Vitro* & *in Vivo* Tools for Preclinical Translation

15.00 Studying Catabolism & the Journey Taken by the ADC

- More details to follow

Ashutosh Pathak, Vice President & Global Head, Medical Affairs, **Ascentage Pharma**

Reviewing How Drug Product & Formulation Enhances Process Development

15.00 Preformulation & Analytical Characterisation of ADCs

- Discussing screening methods for the early formulation development of ADCs
- Extended insights into Dynamic light scattering as powerful screening tool
- Overview on Polysorbate analytics and stability

Steffan Woell, Principal Scientist, **Merck**

Scientific Programme Day 1

Tuesday, 3rd March

15.30 Site-selective Antibody Conjugation Enabled by Disulfide Bridging & Cysteine-to-lysine Transfer

- The development and optimisation of the Next Generation Maleimide and Pyridazinedione reagent classes for the construction of ADCs
- The rapid formation of robustly stable ADCs from native antibodies by rebridging the native disulfide bonds
- A new approach to antibody conjugation will be presented, in which cysteine residues are employed as hooks to deliver acylating residues to specific lysines

Jamie Baker, Reader in Chemical Biology, **University College London**

15.30 Broadening the Therapeutic Window with Bispecific ADCs, do Bispecific Drug Conjugates Improve Targeting?

- Discuss ZW49, a biparatopic antibody-drug conjugate armed with our proprietary ZymeLink™ cytotoxic payload
- *In vivo* efficacy compared to approved and leading clinical-stage HER2-targeted ADCs
- GLP toxicology studies predict an enhanced therapeutic window enabling extended dosing in the clinic

John Babcook, Senior Vice President of Discovery Research, **Zymeworks**

Clinical Content

15.30 Reductive Desulfuration as an Important Tool in Detection of Small molecule Modifications to Payload of Antibody Drug Conjugates

- Method development of desulfuration of the thioether linker in ADC. The reaction conditions were optimized for release of the payload to take advantage of the high resolution and high mass accuracy of the Orbitrap to characterize metabolism of the payload.
- Application of the technique in model ADCs. The resulted information enables characterization of the payload of ADC following its incubation in hepatocytes, liver microsomes and buffers as illustrated by the identification of a hydrolyzed thiosuccinimide ring of SigmaMAb ADC mimic following incubation in buffer.

Jack Wang, Senior Scientist, **Johnson & Johnson**

15.30 ThioBridge™ as a Tool for the Design, Optimisation & Manufacture of ADCs

- Demonstrating how ThioBridge™ conjugation is a flexible approach for producing stable ADCs with defined location and extent of drug loading
- Highlighting how the simple design of ThioBridge™ ADCs means they can easily undergo a systematic determination and optimisation of their *in vitro* and *in vivo* biological properties
- ThioBridge™ targets natural disulfides with highly reproducible conjugation profiles at milligram to gram scales
- Evaluating Abzena's capabilities for design, optimisation and manufacturing of ADCs

Mark Frigerio, Director & Vice President - Design, Developability & Chemistry, **Abzena**

16.00 Exploring how a New Linker Technology can Improve the ADC Tolerability

- Discussing novel approaches to site-specific conjugation of antibodies using symmetrical PBD payloads
- Understanding the importance of linker payload flexibility in this context
- Examining the impact of this technology on therapeutic index improvement

Balakumar Vijayakrishnan, Group Leader - Conjugation, **Spirogen**

16.00 Bispecific ADCs Targeting HER2: Intracellular Trafficking of the Antibody Dictates the Choice of Linker-Payload

- Assessing how Bispecific ADCs bridging HER2 and high turnover proteins travel to lysosomes and improve efficacy of HER2 ADCs with stable linker-DM1
- Analysing Biparatopic HER2 ADCs that induce target recycling and require cleavable linker for greater efficacy
- Combining various bispecific antibody approaches with correct linker-payload technology may allow to generate ADCs with better efficacy and safety profiles

Julian Andreev, Senior Staff Scientist & Research Fellow, **Regeneron Pharmaceuticals**

16.00 Alternative Assays – Immunogeneicity & Metabolite ID

Session Reserved

16.00 Process Development & Manufacturing of Cysteine Linked Antibody-Drug Conjugates – Control of Product Heterogeneity

- Addressing challenges and strategies for ADC manufacturing
- Assessing control of product heterogeneity
- Sharing improvements for future processes

Guy De Roo, Project Leader, Downstream Processing, **Synthon**

16.30 Afternoon Refreshments & Networking

Scientific Programme Day 1

Tuesday, 3rd March

Sharing an Update on the ADC Clinical Pipeline & How this can be used in the Manufacturing of ADCs

Letrishka Anthony
Senior Analyst
Beacon Targeted Therapies
Hanson Wade

17.30 Reviewing the ADC Clinical Pipeline

- Update on the key movements in the clinic
- Gain insight into the rapidly evolving pipeline
- Analyse of novel clinical ADCs

Lisa McDermott
Head of Process & Analytical Development
Merck

18.00 Process Understanding & Automated Processing Development to Ensure First Pass Manufacturing Success of ADCs

- Explore studies needed for clinical supplies and for commercial readiness with the goal of providing evidence of process consistency
- Review the use of automated systems for gathering information for early phase process transfers to manufacturing
- Does that ensure appropriate ranges are evaluated and ensure deep process understanding?

Alain Beck
Senior Director, Biologics CMC & Developability
Pierre Fabre

18.30 Chair's Closing Remarks

18.40 Scientific Poster Session

After the formal presentations have finished, the learning and networking carries on. The Poster Session is an informal part of the conference agenda, allowing you to connect with your peers in a relaxed atmosphere and continue to forge new and existing relationships. During this session over 25 scientific posters will be presented from novel linker designs to validation of site specific conjugation technologies and more informative in vivo models.

"A great place to meet peers and partners, learn about novel ADC approaches and better understand the direction, the field is headed for"

Tubulis GmbH

Scientific Programme Day 2

Wednesday, 4th March

Alain Beck
Senior Director, Biologics CMC & Developability
Pierre Fabre

8.50 **Chair's Opening Remarks**

Rakesh Dixit
Chief Executive Officer & Founder
BioNavigen

9.00 **ADC Targets & Payloads: When Friends Become Foes**

- Understand the navigation of targets and payloads for ADCs
- Wrong pairing of targets and payloads: turning friends into foes
- Evaluate strategies for selection of targets and payload for improving the therapeutic index
- Uncover translational medicine strategies to maximise TI

Trevor Hallam
Chief Scientific Officer
Sutro Biopharma

9.30 **Targeted Immunostimulants; A Promising Approach to *In Situ* Immunisation**

- Assess the role of immunogenic cell death in propogating more robust immune responses in patients on combination therapy with immunotherapeutics such as check-point inhibitors; a promising approach to increase durability of response
- Review how targeted immunostimulators now look to generate innate immune responses to tumours while increasing systemic tolerability
- Examine how homogeneous antibody drug conjugates optimised to deliver combinations of mechanistically different payloads demonstrate that targeted "*in situ* immunisation" is feasible

Clinical Content

Daejin Abidoye
Vice President, Clinical Development
Seattle Genetics

10.00 **Combining ADCs & Immunotherapy: Mechanistic Insights & Clinical Observations**

- Discuss preclinical data demonstrating monomethyl auristatin E (MMAE) has the potential to drive immunogenic cell death
- Review preclinical and biomarker data on MMAE that support the induction of inflammatory cytokines and innate inflammatory responses which are consistent with MMAE-induced ICD
- Share insight from how our data provide the rationale for combining our ADCs with immuno-oncology therapies including PD-L1 checkpoint blockade
- Share data from combinations of ADCs with PD-1 inhibitors with implications for future development of these combinations

10.30 **Morning Refreshment & Networking**

Scientific Programme Day 2

Wednesday, 4th March

Discovery Chemistry Stream

How Potent do we Go? Comparing High DAR with High Potency

11.30 The Dark Side of the Moon: The Chemistry Behind Strategies for Building Small Molecule Drug Conjugates – a Legacy

- Review the conceptual design of a small molecule drug conjugate (SMDC) for targeted therapies of cancer
- Explore self-immolative linker systems: from theoretical design to practical synthesis
- Engineering spacer units: their role in the control of physical properties and to switch toxicity profiles of Folate-Drug Conjugates
- Selection standards and novel design of payloads: from tradition to innovation

Iontcho Vlahov, Vice President Discovery Chemistry, **Endocyte**

12.00 Impact of Linker Chemistry & Metabolite Profile on the Performance of ADCs with KSP-inhibitor Payloads

- Evaluate KSP inhibitors; versatile new payload class for the generation of highly potent and selective ADCs
- Understand how linker composition and metabolite profile can be adapted to the requirements of individual targets

Hans-Georg Lerchen, Chief Scientist, Medicinal Chemistry, **Bayer**

Discovery Biology Stream

Tricks of the Trade; Antibody Engineering Techniques to Try to Improve the Off-Target Toxicity Profile

11.30 Modifying the Antibody to Reduce Non-Specific Uptake in the Tumour

- More details to follow

John Harlan, Senior Principal Research Scientist, **AbbVie**

12.00 Prodrugs as Drug Delivery System in Oncology

- What is a prodrug?
- Reviewing the design of prodrugs targeting the tumour microenvironment
- Reviewing the design of prodrugs targeting the tumour cell

Charles Skarbek, Bioorganic Chemistry Post-doctoral Researcher, **University of Paris-Sud**

Translational Steam

The Balancing Act: Delivering Enough ADC for Meaningful Activity Without Triggering Potency

11.30 Potential Mechanisms of ADC Off-target Toxicities & Strategies/ Opportunities to Improve the Overall TI of ADCs

- Reviewing mechanisms of action for antibody drug conjugate off target toxicities
- Analysing mechanisms of action for antibody drug conjugate off target strategies
- Delving into opportunities to improve clinical index of ADCs

Prathap Kumar Mahalingaiah, Senior Scientist III, **AbbVie**

12.00 MUC13 mucin, A Novel Candidate for Drug-Antibody Conjugates for GI Cancers

- Learn about MUC13 as a novel target for
- ADC
- Discussion about novel MUC13 antibodies we have developed
- Learnings regarding our progress on MUC13 antibody drug conjugate project

Subhash Chauhan, Professor, **University of Tennessee**

CMC Stream

Sharing Lessons Learned from Scaling Up to Commercial Scale Manufacturing

11.30 Panel Discussion: Aligning the Complex ADC Supply Network to Make Drug Products for Patients

- Evaluate strategies for supply network alignment
- Identification of risks in the supply chain

Jens Lorhmann, Disease Area Head, Oncology, **Novartis**

12.00 Synthesis of ADC Payloads – Challenges and Opportunities

- Payload selection is critical to ensure a suitable therapeutic index is achieved for ADCs
- Synthetic Chemistry plays a key role in modifying and delivering linker-payloads to meet this objective
- Significant challenges and opportunities exist within Synthetic Chemistry which need to be addressed to deliver successful ADCs

Jeremy Parker, Senior Principal Scientist - New Modalities & Tissue Targeting, **AstraZeneca**

Scientific Programme Day 2

Wednesday, 4th March

12.30 Diels-Alder Bioconjugation for Production of Homogeneous & Stable ADCs

- Gain insights on how Diels-Alder bioconjugation utilises maleimide payloads for attachment to antibodies
- Examine how Diene functional groups are incorporated into antibodies via linkers or non-natural amino acids
- Uncover how ADCs can be produced in a one-step process
- Assess resulting ADCs that are stable in serum and exhibit potent tumour growth inhibition *in vivo*

James (Jim) Christie, Scientist, **AstraZenca**

12.30 Development of BT5528 into the Clinic: A Bicycle Toxin Conjugate Targeting EphA2 for the Treatment of Solid Tumours

- Showcasing the development of BT5528 and the journey into the clinic
- Case Study: addressing a "toxic" target with a new modality
- Differentiation: how BT5528 delivers efficacy without toxicity associated with previous ADC approach

Gavin Bennet, Director & Project Leader, **Bicycle Therapeutics**

Clinical Content

12.30 Development of a Probody Drug Conjugate (PDC) Targeting CD71 for the Treatment of Cancer

- Evaluating the Probody/PDC platform
- Discussing safety and efficacy in animal models
- Reviewing diagnostics assay development and validation

Luc Desnoyers, Senior Director of Translational Sciences, **CytomX Therapeutics**

12.30 CMC Considerations for Targeted Thorium Conjugates - TTCs

- More details to follow

Markus Eser, Laboratory Head, **Bayer**

13.00 Lunch & Networking

Exploring how Changing the Format of the ADC, Altering the DAR & Shifting Potency can Ultimately Impact Your ADC

Thomas Pillow
Senior Scientist
Genentech

14.30 Chimeric Protein Degraders as ADC Payloads

- Moving beyond pan-cytotoxics for improved tolerability
- Increasing DAR for lower potency payloads
- Developing new linkers for alcohols

Samuele Cazzamalli
Research Scientist
Philogen

15.00 Small Molecule-Drug Conjugates: Getting Small to Enhance Targeting

Clinical Content

- Understanding how ADC products are limited by their slow and inefficient accumulation in solid tumours Small Molecule-Drug Conjugates have been recently proposed as an alternative approach to deliver potent cytotoxic compounds to the neoplastic site and to solid metastatic lesions
- Acetazolamide is a small organic compound that exhibits a high binding affinity to the tumour-associated antigen Carbonic Anhydrase IX (CAIX), a marker of Renal Cell Carcinoma and of hypoxic tumours. We compared acetazolamide-based SMDC products to anti-CAIX ADCs for their ability to reach tumours *in vivo* and for their anti-tumour performance
- Analysing recent clinical trial data that have confirmed the efficient accumulation of an acetazolamide-based radiotracer (PHC-102) to solid tumours and metastatic lesions in Renal Cell Carcinoma patients

Scientific Programme Day 2

Wednesday, 4th March

Phil Howard
Chief Scientific Officer
Spirogen

15.30 Modulating the Potency & Physicochemical Properties of PBD Payloads

- Analysing next generation PBD payloads
- Discussing Warhead optimisation
- Exploring the effect of N10 Capping groups
- Evaluating DAR1 PBD ADCs

16.00 Afternoon Refreshments & Networking

Delving into Solid Tumours & ADCs Outside of Oncology

Andrea Gonzalez-Munoz
Research scientist
AstraZeneca

17.00 Overview: How an Antibody-drug Conjugate Cures a Stage 1 Model of African Trypanosomiasis (Sleeping Sickness)

- Understanding the emerging role of ADCs in non-oncological therapeutic areas
- Gain insight on a generation of an ADC against a Trypanosoma brucei HpHb receptor
- Examine how a single dose of this ADC cures the first stage of African Trypanosomiasis in a mouse model

Bart de Goeij
Assistant Director
Genmab

17.30 Tisotumab Vedotin – A Tissue Factor-Targeting Antibody-drug Conjugate for the Treatment of Advanced Solid Tumours

- 5 years after FIH, what have we learned?
- Manageable safety profile
- Antitumour activity in patients with metastatic cervical cancer

Clinical Content

Alain Beck
Senior Director, Biologics CMC & Developability
Pierre Fabre

18.00 Chair's Closing Remarks

Post-conference Workshop Day

Thursday, 5th March

Workshop G: Advanced Design of ADCs: Principles & Applications with Next Generation Linkers & Site Specific Technology

9.00-12.00

Let's explore various ways to improve the therapeutic window of ADCs using a rational approach to improve clinical performance by building a better molecule. By incorporating improvements in solubility as well as attachment stability, great strides can be made.

Join this workshop to discuss various methods for obtaining a defined DAR, and the pros and cons of several key approaches. Particular attention will be given to **dual and multi-warhead ADCs, and the various ways to achieve controlled multivalency on native and engineered proteins**. Lastly, with the emergence of Immunooncology, dual binding bi-specific antibodies will be discussed as a platform for ADC conjugations.

Agenda Summary:

- Welcome and Introductions
- Background and Defining the Challenge
- Solubilising the Drug-Linker
- Stabilising the Linker
- Site-Specific Strategies for Success
- Multi-valency and Dual-Warheads
- Bi-specific constructs as ADC platforms

Rick Powers, Independent Consultant

Ed Ha, Founding Principal Scientist, **AngieX**

Workshop H: Exploring Novel Mechanism of Actions, Optimising Payload & Linker Chemistry & Deepening Understanding of Payload Driven Toxicities

13.00-16.00

Discussions will focus on how payload-linker combinations can affect ADC clinical activity and toxicities when attached to antibodies, and **how the most appropriate payload-linker combination can be chosen** for a particular antibody and/or cancer type.

Attend this workshop to explore the scientific biological rationale for maximising the synergy of ADC payload- linker combinations.

This workshop will enable you to:

- Improve your understanding of the most desirable properties of payloads and linkers
- Review current payload-linker combinations which are enhancing the therapeutic window
- Evaluate past strategies to improve and balance: payload potency, impact of homogeneous conjugations on PK/PD, protein/nucleic acid payloads & synergy with I/O
- Explore payload and linker combinations currently at the discovery or development stages
- Learn to develop linker-payloads that will not release prematurely
- Discover important considerations for designing the optimum payload-linker

Rick Powers, Independent Consultant

Ed Ha, Founding Principal Scientist, **AngieX**

CMC Day

Thursday, 5th March

8.50 Chairs Opening Remarks

Alain Beck, Senior Director, Biologics CMC & Developability, **Pierre Fabre**

Analysing the Lessons Learned to Improve Scale Up

9.00 Product Understanding : The Challenge for Stochastic Conjugates to Prepare Charge Variants & Assess their Impacts on Critical Quality Attributes

- Understand the requirement behind the Product Understanding & related challenges for charge variants issued from stochastic conjugates
- Delve into the purification path to deliver charge variants
- Share impact on Critical Quality -Attributes of these charge variants

Eric Lacoste, Head of Bio-Organic Team & Chemistry, Manufacturing, Control & Project Manager, **Sanofi**

9.30 Fine-Tuning Process Development, Scale-up & GMP Manufacturing of a Novel ADC Technology Platform

- Overview of complex supply chain architecture for ADC manufacturing
- Evaluating a QbD-based strategy to process validation of key process parameters
- Analysing process scale-up case studies

Dan Custar, Associate Director, Drug Substance CMC, **Mersana Therapeutics**

10.00 Speed Networking

10.50 Morning Refreshments

Analytical Lessons Learned from Commercial Manufacturing for ADCs

11.30 ADC CMC & Developability: Input of State-of-the-Art Analytical Methods

- Demonstrating Quality Target Product Profile and Critical Quality Attributes
- Reviewing multilevel and multidimensional analytical methods
- Discussing structure assessment and quality control

Alain Beck, Senior Director, Biologics CMC & Developability, **Pierre Fabre**

12.00 Lessons Learned During Drug Product Development of ADCs

- Tackling stability and formulation challenges
- Exploring new processes and establishing external partnerships
- Addressing issues during clinical administration
- Assessing ADC lyophilization cycle development

Daniel Shweizer, Fellow & Project Leader, **Novartis**

12.30 Mastermind Session: ADC Formulation/Fill Finish Development readying for Commercial Scale Manufacturing

- More practical and highly interactive breakout roundtables where attendees can crowd-source solutions and share opinions around pre-assigned topic areas.
- A valuable chance for attendees to unite around hot topics and debate best practice. No more sitting quietly, this is a dedicated opportunity for you to voice your experiences and identify unique solutions
- Discussing solutions to overcome aggregation challenges
- Case studies on progressive formulation and fill finish methods

13.00 Lunch & Networking

Considerations for Scaling Up Your Manufacturing Operations from Phase II & Beyond

14.00 ADCs Developability Assessment: from Research to Development of New Candidates

- Evaluation of new candidates for a given target based on limited characterization data
- Early stability assessment by means of short-term stress study
- Criteria for selection of best candidates for development

Pierre Guibal, Deputy Head, Analytical Development, BioAnalytics, **Sanofi**

14.30 From Research to Commercial: A Conjugation Scale-up Primer

- What is involved in scale-up beyond volume
- What are the challenges from development to Phase I and beyond
- Managing expectations in moving to GMP manufacturing

Rich Reynolds, Principal Scientist, Conjugation Process Development, **Seattle Genetics**

15.00 Panel Discussion: Simplifying Your Global Manufacturing Supply Chain

- What went wrong? Discussing lessons learned from managing late stage manufacturing supply chains
- Effectively managing complex global supply chains
- Exploring opportunities to work with partners in emerging ADC geos such as Asia

15.30 Chairs Closing Remarks

Alain Beck, Senior Director, Biologics CMC & Developability, **Pierre Fabre**

Partner with Us

The antibody drug conjugate community is constantly growing and **eager to stay ahead of the curve through assessing innovative technologies**. If your company offers services and solutions that would benefit our audience, we'd love to hear from you.

Partnering with this event is a proven way to attract the attention of key decision makers and influence their choices at a critical time; **this is your fastest route to organisations prioritising ADC development.**

With the ADC space evolving and progressing at the rate it is, this event is the perfect opportunity to showcase your brand, your message and your reputation to the ADC community.

This could involve **presenting on the agenda, hosting networking sessions, exhibiting, or brand exposure**. But our focus and reach is much wider. From being fully integrated across a multi-channel communication strategy, to targeted introductions to the right individuals in your target market, we have opportunities that offer it all.

"World ADC London offered an incredible opportunity to engage subject experts from many players in the ADC space. The event was the right size to engage meaningful discussions and exchange useful updates with CDMOs and Pharma developers alike. The sessions and breaks were well organised and offered a nice environment for effective learning and networking. I look forward to staying in touch with the group"

AbbVie

Let's talk, contact us today to find out how we can help you achieve your business goals faster.

Rob Keast
Commercial Director
Tel: +44 (0)20 3141 8700
Tel (US): + 1 415 735 3289
Email: adc@hansonwade.com

Harriet Menzel
Commercial Director
Tel: +44 (0)20 3141 8700
Tel (US): + 1 415 735 3289
Email: adc@hansonwade.com

Who You'll Meet

Your World ADC Experience



Seniority of Attendees



Attendance by Company:



Our Partners

Senior Partner

MERCK

Partners

AVIPEP Therapeutics
ABZENA Enabling better biopharmaceuticals
Aj AJINOMOTO BIO•PHARMA SERVICES
BSP PHARMACEUTICALS
cerbios Fostering Value through Innovation
Heraeus
IKSUDA THERAPEUTICS
Lonza
NBE therapeutics
NJ BIO PHARMACEUTICALS
novasep passion & smart processes
SafeBridge CONSULTANTS, INC. A TRINITY CONSULTANTS COMPANY
SCIEX

Exhibitors

CARBOGEN AMCIS A Dalhousie Group Company
MINAKEM FINE SERVICES FOR LIFE
QUALITY ASSISTANCE Contract Research Organisation
reachbio RESEARCH LABS
solocontainment

Pricing, Venue & Registration

3 Easy Ways To Book

www.worldadc-europe.com/register

Email: register@hansonwade.com

Tel: +44 (0)20 3141 8700

Team Discounts

Get value for money using special team discounts:

- **20% discount – 5+ delegates**
- **15% discount – 4 delegates**
- **10% discount – 3 delegates**

Please note that discounts are only valid when 3 or more delegates from one company register at the same time. Not for profit rates are available - email adc@hansonwade.com

Maximise Your Onsite Experience by Attending as a Team

1. **Maximise your team's learning opportunity** at this conference. Sending a team means that you can make sure that between you, you benefit from all of the topics across the 4 streams.
2. **More effective networking and relationship building.** Ensure you've met with all potential new partners, existing collaborators and colleagues.
3. **Value for money.** Tiered group rates apply when three or more attendees book and pay at one time. Corporate rates can be applied if you are planning on sending multiple attendees from different sites and departments.

Package Details*	Register & Pay before Friday, 29th November 2019	Standard Prices
Gold (Full 4 Day Access Pass): Conference + 2 Workshop Days OR Conference + Workshop Day & CMC Day	£3795 + VAT **(save £500)**	£4095 + VAT **(save £200)**
Silver (3 Day Pass): Conference + 1 Workshop Day Conference + CMC Day	£2797 + VAT **(save £400)**	£3097 + VAT **(save £100)**
Bronze (2 Day Pass): Conference only	£1799 + VAT **(save £300)**	£2099 + VAT

*VAT will be charged at 20%

Terms & Conditions Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time. Changes to Conference & Agenda: Hanson Wade reserves the right to postpone or cancel an event, to change the location or alter the advertised speakers. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities. Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Database Manager, Hanson Wade, Suite A, 6 Honduras Street, London EC1Y 0TH

Venue

London Novotel West
1 Shortlands, Hammersmith,
London W6 8DR
United Kingdom

www.novotellondonwest.co.uk